(Q81725630)

English

Certolizumab pegol

scientific article published on 01 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Certolizumab pegol (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Stephan R. Targan

2

object named as

Stephan R Targan

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

3

object named as

Uma Yasothan

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Peter Kirkpatrick

5

object named as

Peter Kirkpatrick

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Gil Y Melmed

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Delphine Hanicq

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

1 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

641-642

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

https://scigraph.springernature.com/pub.10.1038/nrd2654

0 references

The immunological and genetic basis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Evolving knowledge and therapy of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2654

31 March 2020

Identifiers

10.1038/NRD2654

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18670430%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81725630&oldid=1988183387"